Please use this identifier to cite or link to this item:

Title: Inhibition of muscle fibrosis and improvement of muscle histopathology in dysferlin knock-out mice treated with halofuginone
Issue Date: 2013
Publisher: F. Hernández y Juan F. Madrid. Universidad de Murcia: Departamento de Biología Celular e Histología
Citation: Histology and Histopathology, vol. 28, nº 2, (2013)
ISSN: 1699-5848
Related subjects: CDU::6 - Ciencias aplicadas::61 - Medicina
Keywords: Muscular dystrophies
Abstract: Absence of, or loss-of-function mutations in the dysferlin gene (dysf) result in dysferlinopathy, characterized by increased muscle inflammation, collagen deposition and deterioration in muscle function. We evaluated halofuginone efficacy in improving muscle histopathology in mice with deleted dysf transmembrane domain. Quadriceps sublumbar and longissimus muscles of 9-month-old dysf-/- mice treated with halofuginone for 4 months exhibited a reduction in centrally-nucleated myofibers, inflammatory infiltrates and collagen content. Late onset of dysferlinopathy makes it ideal for evaluating the efficacy of early treatments on late outcome. The dysf-/- mice were treated with halofuginone for 3 to 4 months starting at 1, 5 or 9 months of age, and quadricep muscle histopathology was evaluated at 12 months. Collagen content and number of centrally nucleated myofibers decreased after early halofuginone treatment, administered when myofibers with central nuclei and inflammatory infiltrates are evident, but there was almost no fibrosis. When administered at the beginning of fibrosis it resulted in a further decrease in the number of centrally-nucleated myofibers with no additional decrease in collagen levels. Cardiac fibrosis was almost completely abolished following early halofuginone treatment. Halofuginone inhibited Smad3 phosphorylation and its translocation to the nucleus and increased the activity of matrix metalloproteinases 9 and 2 responsible for resolution of pre-existing collagen. Macrophage and myofibroblast invasion into the dystrophic muscle at the site of myofibers with central nuclei was inhibited by halofuginone. These results suggest that early halofuginone treatment can prevent the late outcome of dysferlinopathy and can cause resolution of the established fibrosis when administered at later stages.
Primary author: Halevy, Orna
Genin, Olga
Barzilai-Tutsch, Hila
Pima, Yaniv
Levi, Oshrat
Moshe, Itai
Pines, Mark
Document type: info:eu-repo/semantics/article
Number of pages / Extensions: 16
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Vol.28, nº 2 (2013)

Files in This Item:
File Description SizeFormat 
Halevy-28-211-226-2013.pdf23,84 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons